Overview

Quantum Biology DAO is a BioDAO funding a corner of science most drug-focused DeSci projects never touch: quantum biology, the study of how quantum-mechanical effects — coherence, entanglement, spin — shape processes inside living cells. Where VitaDAO (longevity), CryoDAO (biostasis), and Curetopia (rare disease) each organise around a therapeutic goal, Quantum Biology DAO organises around a physical question and the instrument needed to answer it. It launched publicly in October 2024 out of research originally based at UCLA, and is part of the BIO Protocol (bio.xyz) network of decentralized-science DAOs.

The DAO was admitted to the BIO Incubator's second cohort on 17 October 2024, alongside Long COVID Labs and Curetopia — the three early admissions that seeded Cohort 2.

The science: weak magnetic fields and living cells

Quantum biology asks whether biological systems exploit quantum effects that survive the warm, wet, noisy interior of a cell — long assumed too chaotic to preserve quantum states. The DAO's stated aim is to understand the physics behind weak magnetic-field effects so that cellular processes can be deliberately influenced: the team names oxidation rates, cellular repair, and cell-division rates as targets. If weak, precisely-tuned magnetic fields can nudge these processes, the applications span health and longevity, biomanufacturing, and drug discovery.

This is deliberately upstream, high-risk basic science — the kind that struggles for grant funding precisely because it questions a settled assumption. That funding gap is exactly the problem DeSci exists to attack.

The quantum microscope

The DAO's flagship project is a quantum microscope — an instrument built to observe quantum phenomena happening in real time inside living cells, developed in partnership with the Quantum Biology Institute, a US non-profit. Building the tool is the point: much of quantum biology has been stuck on the lack of instruments that can measure quantum states in a biological sample without destroying them. Funding an instrument rather than a molecule makes Quantum Biology DAO structurally distinct from every IP-NFT-based BioDAO in this directory, which fund a research asset that resolves to intellectual property.

The underlying research raised roughly $3M in its first three years from government and private sources at UCLA before moving into the DAO structure, and the DAO has directed a $1.2M grant to the Quantum Biology Institute for foundational research.

Founders

Quantum Biology DAO is co-founded by Clarice Aiello (Chief Scientific Officer) and Geoff Anders (CEO). Aiello is a physicist described as a world-leading scientist in quantum biology, who led the quantum-biology research group at UCLA; Anders founded the research organisation Leverage and brings experience running interdisciplinary teams. The scientific team has hired for optical systems, molecular biology, and protein engineering — the mix a quantum-microscope build demands. Naming a credentialed principal investigator, rather than pseudonymous stewards, is characteristic of the bio.xyz BioDAO model, where a real lab sits behind the token.

The $QBIO token and governance

Quantum Biology DAO held its token generation event in January 2025 on the BIO Protocol launchpad — the QBIO/WETH auction (#560) — raising funds on Ethereum to bankroll the microscope and grant programme. $QBIO is a governance and funding token, not equity: like other bio.xyz BioDAOs it carries the right to vote on research direction and grant allocation, curated by $BIO holders who stake into and co-own the BioDAO through the launchpad. Token holders steer an open competition for research grants; the DAO also owns a portion of the Quantum Bio Incubator, a Delaware C-corporation chartered to spin quantum-biology research into companies.

Place in the DeSci landscape

Within the Molecule / bio.xyz lineage, Quantum Biology DAO occupies a rare niche. Most BioDAOs are therapeutic-area DAOs that fund a pipeline toward a drug or intervention. Quantum Biology DAO is a foundational-science-and-tooling DAO: its deliverable is knowledge and an instrument, and its bet is that discovery upstream of any single disease unlocks many downstream applications. That places it closer in spirit to a research-infrastructure play than to a single-asset IP-NFT bet — a useful data point for anyone mapping how far the DeSci funding model can stretch beyond the drug-development template it was first built for.

How Caper approaches this

Quantum Biology DAO is a science-funding organisation, not a governance protocol, so Caper is not a competing tool — but the two share a design instinct worth naming. A DAO that funds long-horizon basic research needs its members' influence to track genuine commitment, not just the size of a wallet that walked in yesterday. Caper's vote weight is (held × votes) / (supply × circulation): it multiplies tokens held by votes actually earned through participation, so a large bag alone can't capture the decision without a record of showing up. And when a member exits, that same weight sets their share — funding decisions and the right to leave are computed from the identical, earned quantity. For an organisation betting patient capital on science that may take years to pay off, aligning control and exit with earned participation is exactly the property that keeps a treasury pointed at the mission. See how Caper proposals work and how a caper raises funds.